| From: tuck | 12/22/2017 10:04:56 AM | | | | | | Roche munches Ignyta (RXDX). Congrats to whoever was holding this targeted therapy company. Maybe Rick? He was trafficking in shares during one of the secondaries, at any rate. Another one where I looked and almost leapt. But didn't.
Cheers, Tuck |
| | Munch-a-Biotech Today | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| From: nigel bates | 1/8/2018 10:02:44 AM | | | | | | I like these guys - they've played by the book, and (IMO) deserve to stay independent.
GHENT, Belgium, 8 January 2018 - Ablynx NV (Euronext Brussels and Nasdaq: ABLX) (“Ablynx” or the “Company”) today confirmed that on December 22, 2017 it received an unsolicited conditional proposal from Novo Nordisk A/S (CSE: NOVO B) (NYSE:NVO) (“Novo Nordisk”) to acquire all of the outstanding shares of Ablynx for €28.00 (or approximately $33.661) per share in cash and one Contingent Value Right (CVR) linked to two upcoming material events with total potential cash payments over time of up to €2.50 (or approximately $3.01) per share.
The Ablynx Board, with the assistance of financial and legal advisors, and taking into account the interests of all its stakeholders, unanimously concluded that the proposal fundamentally undervalues Ablynx and its strong prospects for continued growth and value creation as it implements its long-term strategic plan of becoming a fully integrated biopharmaceutical company.
Ablynx also confirms that on December 7, 2017, Novo Nordisk made an unsolicited, non-binding and conditional proposal (the “December 7 proposal”) to acquire all outstanding shares of Ablynx for €26.75 (or approximately $31.572) per share in cash. Following careful consideration, the Ablynx Board unanimously concluded that the December 7 proposal fundamentally undervalues the Company and its future prospects. Despite this, on December 19, 2017, Novo Nordisk reiterated its commitment to the December 7 proposal.
“After careful consideration, the Ablynx Board of Directors unanimously determined that Novo Nordisk’s proposal is not in the best interests of the Company and its shareholders as it fundamentally undervalues caplacizumab, the Ablynx pipeline, platform, technology, people, and know how. The Board sees no merit in ceding control of its assets without full upfront value recognition for shareholders and believes the proposed consideration and a complex instrument like a CVR does not constitute a basis for further discussions at this time,” said Dr. Edwin Moses, Chief Executive Officer of Ablynx.
Dr. Moses continued, “With Ablynx’s enormous upside, we are focused on executing on opportunities that have the potential to deliver long-term growth and returns and are confident in our ability to create significant value. The very positive results from our HERCULES Phase III study and our two ongoing Phase II studies validate our ability to execute on our plan to deliver meaningful products to patients that address unmet medical needs where there are currently limited or no therapeutic options. In addition to developing our proprietary pipeline, including preparing for the commercial launch of caplacizumab, we are engaged in a number of exciting strategic collaborations with major pharma companies, further validating the potential of our Nanobody platform. We firmly believe the continued execution of this strategic plan will deliver substantially more value to Ablynx shareholders than Novo Nordisk’s proposal.”
J.P. Morgan is serving as financial advisor to Ablynx and Goodwin Procter LLP and Eubelius CVBA/SCRL are serving as legal counsel.
|
| | Munch-a-Biotech Today | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: Robohogs who wrote (3107) | 1/16/2018 3:55:42 AM | | From: nigel bates | | | | Someone expects more value:
GHENT, Belgium, 16 January 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Van Herk Investments B.V. on 15 January 2018.
Van Herk Investments B.V. notified Ablynx that it has crossed the 10% threshold on 12 January 2018 and now holds 7,629,229 voting securites of Ablynx, representing 10.21% of the current 74,720,644 outstanding voting rights of Ablynx (versus 9.99% notified previously on 11 October 2017)..... |
| | Munch-a-Biotech Today | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: nigel bates who wrote (3108) | 1/16/2018 12:59:55 PM | | From: olivier benrubi | | | | Not the only one
January 16, 2018 01:01 ET | Source: Ablynx NV
multilang-release
REGULATED INFORMATION
GHENT, Belgium, 16 January 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Marshall Wace LLP on 12 January 2018.
Marshall Wace LLP notified Ablynx that as a result of an acquisition of voting securities, it has crossed the 3% threshold on 8 January 2018 and now holds 2,251,187 voting securities of Ablynx, representing 3.01% of the current 74,720,644 outstanding voting rights of Ablynx.
The notification contains the following information:
Reason for the notification: acquisition or disposal of voting securities or voting rights Notification by: a person that notifies alone Persons subject to the notification requirement: Marshall Wace LLP Transaction date: 8 January 2018 Threshold that is crossed: 3% Denominator: 74,720,644 Details of the notification: Marshall Wace LLP holds 2,251,187 Ablynx shares with voting rights |
| | Munch-a-Biotech Today | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| |
